Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Rand... by Barbara Rossetti, Micol Ferrara, Lucia Taramasso, Francesca Bai, Francesca Lombardi, Nicoletta Ciccarelli, Miriam Durante, Francesca Alladio, Federica Bonazza, Ilaria Rancan, Francesca Montagnani, Antonio Di Biagio, Antonella d’Arminio Monforte, Maurizio Zazzi, Massimiliano Fabbiani, for DOBINeuro study group

Subjects: Get full text

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide by Aleksandra Berkan-Kawińska, Anna Piekarska, Hanna Berak, Włodzimierz Mazur, Aleksander Garlicki, Magdalena Tudrujek-Zdunek, Beata Lorenc, Dorota Dybowska, Łukasz Socha, Anna Parfieniuk-Kowerda, Robert Flisiak

Subjects: Get full text

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study by Hernando Knobel, Esperanza Cañas-Ruano, Ana Guelar, Pablo Knobel, Judit Villar-García, Alicia González-Mena, Ceclia Canepa, Itziar Arrieta-Aldea, Augustin Marcos, Agustí Abalat-Torrres, Roberto Güerri-Fernández

Subjects: Get full text